<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022555</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02398</org_study_id>
    <secondary_id>AMC-029</secondary_id>
    <secondary_id>U01CA070019</secondary_id>
    <secondary_id>CDR0000068830</secondary_id>
    <nct_id>NCT00022555</nct_id>
  </id_info>
  <brief_title>Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma</brief_title>
  <official_title>A Phase I Trial of Combination Bryostatin-1 and Vincristine in HIV-Related B-cell Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of bryostatin 1 plus vincristine in treating&#xD;
      patients who have recurrent or refractory lymphoma. Drugs used in chemotherapy use different&#xD;
      ways to stop cancer cells from dividing so they stop growing or die. Bryostatin 1 may help&#xD;
      vincristine kill more cancer cells by making them more sensitive to the drug&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of bryostatin 1 when administered with vincristine in&#xD;
      patients with recurrent or refractory HIV-related B-cell lymphoma.&#xD;
&#xD;
      II. Determine the toxicity profile of this regimen in these patients. III. Determine the&#xD;
      objective response and survival of these patients treated with this regimen.&#xD;
&#xD;
      IV. Determine the immunomodulatory effects of this regimen on interleukin-2 (IL-2), IL-2&#xD;
      receptor, and IL-6 cytokine levels in these patients.&#xD;
&#xD;
      V. Determine the effect of this regimen on CD4+ lymphocyte count and HIV load in these&#xD;
      patients.&#xD;
&#xD;
      VI. Determine the effect of this regimen on the human herpes virus-8 load in these patients&#xD;
      with body cavity-based lymphoma.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of bryostatin 1.&#xD;
&#xD;
      Patients receive bryostatin 1 IV continuously on days 1 and 15 and vincristine IV over 5&#xD;
      minutes on days 2 and 16. Treatment continues every 4 weeks for a minimum of 2 courses in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of bryostatin 1 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of bryostatin-1 defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting toxicities</measure>
    <time_frame>4 weeks</time_frame>
    <description>Defined as any &gt;= grade 2 neuropathy, other grade 3 non-hematologic toxicity (excluding alopecia and grade 3 nausea and vomiting that is responsive to standard pharmacologic intervention) or grade 4 hematologic toxicity in 2 or more patients. The incidence of toxicity related dose reduction and treatment discontinuation will be summarized for each dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunomodulatory effects of this combination</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Measured by a solid phase Enzyme Amplified Sensitivity Immunoassay.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>AIDS-related Diffuse Large Cell Lymphoma</condition>
  <condition>AIDS-related Diffuse Mixed Cell Lymphoma</condition>
  <condition>AIDS-related Peripheral/Systemic Lymphoma</condition>
  <condition>AIDS-related Small Noncleaved Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (bryostatin 1, vincristine sulfate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bryostatin 1 IV continuously on days 1 and 15 and vincristine IV over 5 minutes on days 2 and 16. Treatment continues every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bryostatin 1</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bryostatin 1, vincristine sulfate)</arm_group_label>
    <other_name>B705008K112</other_name>
    <other_name>BRYO</other_name>
    <other_name>Bryostatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bryostatin 1, vincristine sulfate)</arm_group_label>
    <other_name>leurocristine sulfate</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincasar PFS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed B-cell lymphoma&#xD;
&#xD;
               -  Eligible subtypes:&#xD;
&#xD;
                    -  Intermediate or high-grade non-Hodgkin's lymphoma (NHL), defined as&#xD;
                       follicular large cell, mantle cell, diffuse mixed cell, diffuse large cell&#xD;
                       and variants, Burkitt or Burkitt-like, or unclassifiable aggressive&#xD;
                       histologies&#xD;
&#xD;
                    -  Body cavity-based lymphoma or primary effusion lymphoma&#xD;
&#xD;
          -  Evidence of HIV infection&#xD;
&#xD;
          -  Received at least 1 prior systemic chemotherapy regimen with failure to respond or&#xD;
             relapse after completion of first-line therapy, including one of the following&#xD;
             doxorubicin-based combinations:&#xD;
&#xD;
               -  Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)&#xD;
&#xD;
               -  Infusional cyclophosphamide, doxorubicin, and etoposide (CDE)&#xD;
&#xD;
               -  Etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH)&#xD;
&#xD;
          -  Evaluable disease outside of prior radiation port&#xD;
&#xD;
          -  No CNS parenchymal or leptomeningeal involvement&#xD;
&#xD;
          -  No primary CNS NHL&#xD;
&#xD;
          -  No HTLV-1-associated leukemia or lymphoma&#xD;
&#xD;
          -  Performance status - Karnofsky 70-100%&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,000/mm3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL (unless concurrently on indinavir)&#xD;
&#xD;
          -  SGOT and SGPT less than 3 times upper limit of normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
          -  No history of cardiac disease&#xD;
&#xD;
          -  LVEF at least 45% by radionuclide ventriculography&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No active angina pectoris&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No history of symptomatic pulmonary disease&#xD;
&#xD;
          -  Corrected DLCO more than 50% predicted&#xD;
&#xD;
          -  No severe chronic obstructive lung disease&#xD;
&#xD;
          -  No symptomatic restrictive lung disease&#xD;
&#xD;
          -  Recurrent controllable infection (e.g., thrush) on chronic suppressive therapy allowed&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No active significant opportunistic infection (e.g., acute Pneumocystis pneumonia,&#xD;
             cytomegalovirus retinitis on induction or maintenance therapy, acute toxoplasmosis)&#xD;
&#xD;
          -  No grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  At least 24 hours since prior transfusion&#xD;
&#xD;
          -  At least 24 hours since prior colony-stimulating factor therapy&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF)&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent hydroxyurea&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior large-field radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior anticancer therapy and recovered&#xD;
&#xD;
          -  Must be receiving stable antiretroviral regimen of at least 4 weeks duration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scot Remick</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Associated Malignancies Clinical Trials Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIDS - Associated Malignancies Clinical Trials Consortium</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bryostatin 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

